| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ainos Inc. | VELDONA | Mild COVID-19 | Phase 2 | Clinical Hold | oral | COVID-19 |
| Ainos Inc. | VELDONA | Mild COVID-19 | Phase 2 | Clinical Hold | oral | COVID-19 |
| AIxCrypto Holdings Inc Com Par $0.001 | RP-G28 | Lactose intolerance | Phase 3 | oral | Gastroenterology | |
| Akari Therapeutics Plc | Nomacopan - (CORONET) | COVID-19 | Phase 2 | Data Released | Subcutaneous | COVID-19 |
| Akari Therapeutics Plc | Nomacopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Trial Completed | Subcutaneous | Hematology |
| Akari Therapeutics Plc | Nomacopan - (ARREST-BP) | Bullous Pemphigoid | Phase 3 | Trial Discontinued | Subcutaneous | Immunology |
| Akari Therapeutics Plc | Nomacopan | Adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Trial Discontinued | Subcutaneous | Hematology |
| Akari Therapeutics Plc | Nomacopan | Pediatric Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Looking for Funding | Subcutaneous | Hematology |